CD36 serves as a signaling receptor and Free Fatty Acid (FFA) transporter in dyslipidemia: the role of dapagliflozin and alirocumab in downregulating atherogenic dyslipidemia via FFA uptake inhibition- experimental study.

CD36 作為訊號受體與游離脂肪酸（FFA）轉運蛋白在血脂異常中的角色：dapagliflozin 與 alirocumab 透過抑制 FFA 攝取下調致動脈粥樣硬化性血脂異常之作用——實驗性研究